Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note released on Thursday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 0.0 %

Shares of NYSE:BTX opened at $0.21 on Thursday. The firm has a market cap of $12.07 million, a price-to-earnings ratio of -0.37 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The company’s fifty day simple moving average is $1.17 and its 200 day simple moving average is $1.62.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.